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Abstract Logistic regression and Gaussian mixture model (GMM) classifiers
have been trained to estimate the probability of acute myocardial infarction
(AMI) in patients based upon the concentrations of a panel of cardiac
markers. The panel consists of two new markers, fatty acid binding protein
(FABP) and glycogen phosphorylase BB (GPBB), in addition to the traditional
cardiac troponin I (cTnI), creatine kinase MB (CKMB) and myoglobin. The
effect of using principal component analysis (PCA) and Fisher discriminant
analysis (FDA) to preprocess the marker concentrations was also investigated.
The need for classifiers to give an accurate estimate of the probability
of AMI is argued and three categories of performance measure are described,
namely discriminatory ability, sharpness, and reliability. Numerical performance
measures for each category are given and applied.
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The optimum classifier, based solely upon the samples take on admission,
was the logistic regression classifier using FDA preprocessing. This gave an
accuracy of 0.85 (95% confidence interval: 0.78–0.91) and a normalized Brier
score of 0.89. When samples at both admission and a further time, 1–6h
later, were included, the performance increased significantly, showing that
logistic regression classifiers can indeed use the information from the five
cardiac markers to accurately and reliably estimate the probability AMI.
Key words acute myocardial infarction – AMI – cardiac markers – diagnostic
aid – probabilistic classification
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1 Introduction
Coronary heart disease is a narrowing of the coronary arteries which can
cause a heart attack (acute myocardial infarction or AMI). This is the
leading cause of premature death in the developed world, causing one quarter
of all male deaths and one sixth of all female deaths in the UK [1].
An acute myocardial infarction is caused by a coronary artery becoming
completely obstructed, normally due to a blood clot, and blood supply being
lost to an area of the cardiac tissue. Once the cells in the heart loose their
blood supply (cardiac ischemia), their membranes become more permeable
and certain chemicals, previously retained within the cell, are able to pass
through the cell membrane and enter the blood stream. A number of these
chemicals, known as cardiac markers, have been found to be useful in
diagnosing AMI, especially where electrocardiograph (ECG) readings are
inconclusive [2]. Most hospitals will check blood samples from patients with
a suspected AMI for one or two of these markers, usually creatine kinase
MB isoenzyme (CKMB) or cardiac troponin I (cTnI).
If AMI is detected quickly, treatment can be administered either via
drugs or surgery to minimise the effects of the infarct and keep the heart
functioning effectively. The treatments, however, are both financially costly
and may have side effects rendering them risky for patients who have not
had an AMI. It is therefore important to rapidly and accurately assess the
condition of a patient for the correct treatment to be administered.
Certain cardiac markers, most notably cTnI, are very specific to cardiac
tissue damage, but may take as long as 6–12h to reach diagnostic values.
Others, for example myoglobin, can be found in the blood stream at abnormal
levels within 2h of an infarct occurring, but are much less sensitive to AMI:
that is, elevated levels can be caused by many factors other than AMI [2].
Clinical diagnosis is based upon a combination of ECG data, clinical
signs and symptoms, and cardiac marker concentrations. Various artificial
intelligence pattern recognition techniques have been used assimilate some
of this data to assist clinical decision making. Most have focused on using
data from clinical symptoms or ECGs. Perhaps the most influential research
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in this area was by Goldman et al. [3, 4] who presented a decision tree
classifier based on studies of over six thousand patients. The Goldman
Protocol, as the classifier became known, used information from patient
histories, clinical symptoms and ECG measurements, but only returned
binary decisions.
Other techniques have mainly used either logistic regression [5, 6, 7, 8]
or artificial neural networks [9, 10]. The logistic regression based ACI-
TIPI algorithm [5], which attempts to diagnose AMI from computerised
interpretation of ECG signals combined with the patient’s age, gender and
information on chest pain, forms the basis of a commercial software application
by Philips Medical Systems (Andover, Massachusetts, USA) to assist in the
diagnosis of AMI. Most recently, Ellenius et al. have developed a protocol,
based primarily upon neural network analysis of sequential measurements of
combinations of CMKB, myoglobin and cTnI at 30 minute intervals, which
shows promising results [11, 12].
In this work, patient samples were analysed on an Evidence biochip
analyser (Randox Laboratories Ltd.). This analyser automatically measures
the concentrations of five key cardiac markers: the previously mentioned
CKMB, myoglobin and cTnI; and the more recently discovered glycogen
phosphorylase isoenzyme BB (GPBB) and fatty acid binding protein (FABP).
In contrast to other publications in this field, which typically use only one
or two markers, this work has access to the concentrations of five markers
simultaneously, two of which (GPBB and FABP) have not been used in
any previous computer based classification system. These concentrations
are used to construct classifiers which predict the probability a patient has
AMI (rather than a binary ‘AMI’ or ‘non-AMI’ classification).
By giving an accurate probability of AMI, such a classifier can be used
by clinicians as a decision aid, rather than as a replacement for human
decision making. However traditional classifier performance measures, such
as accuracy, are only viable when classifiers produce a binary decision.
Assessing the performance of a probabilistic classifier is a more troublesome
task, and is seldom discussed in the literature. Techniques to accomplish
this are reviewed.
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Two different classifier structures are used, logistic regression and Gaussian
mixture models, together with several preprocessing techniques, in order to
determine the optimal classifier design. Samples were available from patients
upon their admission to hospital and, in many cases, at a second time 1–
6h later. Incorporating a second sample (from the same patient) into the
classifier is shown to improve diagnostic performance, but at the price of
delaying the time before the diagnosis is available.
The long-term aims of this research are to enhance the information
available to clinical staff concerning AMI patients to assist with diagnosis
and treatment. Initially, the concentrations of five markers, instead of the
current one or two, will be provided; this paper is concerned with the next
step: processing these raw marker readings to estimate the probability of
AMI in new patients.
This paper is organised as follows: section 2 explains the study population,
recruitment, sampling and inclusion criteria. Section 3 then discusses the
need for probabilistic classifiers (i.e. classifiers which give a probability of
AMI rather than simply ‘yes’ or ‘no’) and highlights appropriate measures
for assessing the performance of such classifiers. In section 4 two classifiers
are presented: logistic regression and Gaussian mixture models (GMMs),
together with the various preprocessing techniques used. The results when
these classifiers were evaluated on the dataset are given and discussed
in section 5, the conclusions are drawn in section 6 and section 7 gives
suggestions for future work.
2 Study details
Samples for this study were collected from patients entering the Department
of Emergency Medicine, St. James’ Hospital, Dublin, Ireland, between 18
September 2000 and 12 October 2002 as part of a large ongoing study.
A research nurse invited patients entering the department with symptoms
indicative of AMI (typically chest pain) to enrol in the study. Those who
gave their informed consent had a selection of clinical, demographic and
ECG information recorded in a database and an initial blood sample taken.
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A protocol was established which required subsequent blood samples to be
taken every two hours, up to a maximum of ten samples. Due to the nature
of a busy emergency department and the acute nature of the patients’
illnesses, it was not always possible to follow the timing or number of
samples exactly, and a number of patients, especially those with AMI,
withdrew their consent part way through the sampling regime. None of
the patients, however, requested complete withdrawal from the study, so
samples already taken were retained. The sample taken on admission was
labelled T0, and subsequent samples T1, . . . , T9. They were then frozen on
site and transported to Randox Laboratories Ltd. where they were processed
using the Evidence biochip analyser. Follow-up from patient records and
home telephone calls sought to establish the final diagnosis given to each
patient, together with surgical and drug treatments as well as 7 and 30 day
mortality.
Approximately 8% of the patients in the study had an AMI. Preliminary
investigations showed that this small number of patients was insufficient
to reliably construct a classifier. In order to enhance the proportion of
AMI patients, priority was then given to analysing samples from AMI
patients over those from non-AMI ones. Although this meant the prevalence
of each disease in the data set was no longer representative of that in
the study population, it has proved possible to develop and test various
classifier models. Bayes’ theorem can be used at a later time to adjust the
probabilities given by a classifier to correct for the difference in prevalence
of the training population and that in the population on which the classifier
will be used [13].
One of the study aims is to make an early diagnosis of AMI. With this
in mind, patients with a T0 sample taken more than 18h after the onset of
pain were discarded. A second data set was constructed containing both T0
and T1 samples. Patients for this set were further rejected if the T1 sample
was taken more than 6h after T0. This regime gives rise to potentially large
variations in the time between an AMI event occurring and their T0 sample
being taken, and also gives the range between first and second samples
being taken (T1−T0) of 1–6h. These variations are reflective of the clinical
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situation in busy emergency departments, and classifiers constructed from
such data will incorporate an inherent robustness to practical variations in
sampling times.
Finally two studies were omitted from the research because their diagnosis
was uncertain. The first was recorded as having had an AMI, but a later
clinical review concluded the event may have happened whilst in hospital,
probably about 48h after the initial pain onset, and almost certainly after
the T0 and T1 samples were taken. The diagnosis is therefore unreliable
and this patient has been omitted from the study. For the second, clinical
opinion was divided between unstable angina and non-Q wave MI for the
final diagnosis.
This left one set of 159 patients with both a valid diagnosis and T0
measurements, 50 of whom had AMI (31%). The second set, containing
both T0 and T1 measurements had 132 patients, 38 of whom had AMI
(29%).
3 Measures of performance
Many automatic classification systems produce some score, or measure of
certainty in their output, rather than simply a binary ‘yes’ or ‘no’ decision.
This score frequently lies between 0 and 1, and is often referred to as a
probability. Despite this, the score is often hidden from the user. A threshold
is set, above which a value of 1 (or ‘yes’) is returned, and below which a
value of 0 (or ‘no’) is given.
In the field of medical diagnostics, returning the actual probability of a
disease has the potential to be more clinically useful than simply providing
a dichotomous decision. Clinicians are used to dealing with uncertainties
and performing risk assessment, and a probability can provide evidence to
be incorporated the clinician’s patient management strategy. Providing a
dichotomous decision can be perceived as trying to compete with the clinical
judgement and removing decision making from the doctor—de Dombal
labelled such a perception “the kiss of death” to many computer-aided
diagnostic systems [14].
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However, assessing the performance of a probabilistic classifier is more
challenging; when classifiers give a binary output, the only possible measures
of performance depend upon how many patients are diagnosed correctly. If
this is measured over an entire sample population, it is called accuracy,
or non-error rate (NER). If it is only measured over diseased patients, it
is termed sensitivity, or if only measured over healthy ones, specificity. In
many cases, a test or classifier gives a continuous output which is then
thresholded to give a binary decision. Receiver operator characteristic curves
(ROC curves) [15] are a tool to visualise the relationship between sensitivity
and specificity as this threshold is varied, and the area under the ROC curve
(AUROCC) provides a numerical measure of the classifiers’ performance,
which has the advantage of being independent of the threshold.
In the probabilistic realm, however, all of these measures (except AUROCC)
break down. If a probabilistic classifier claims that a healthy sample has an
80% chance of being diseased, it is not possible to say the classifier is ‘wrong’
based on this single sample. Habbema, Hilden and Bjerregaard proposed
three distinct, yet related, quantities for measuring the performance of
probabilistic classifiers: discriminatory ability, sharpness and reliability ([16,
17, 18, 19, 20]), each of which must be considered when assessing the
performance of a probabilistic classifier.
3.1 Discriminatory ability
Discriminatory ability is a measure of how well a classifier can select between
diagnoses. A good classifier should clearly assign high probabilities to the
diseases the patients actual have.
In addition to the well known AUROCC, the normalised Brier score
(Q31 in Habbema et al.’s notation [16]) was used to measure discriminatory
ability in this work. In the case of two mutually exclusive classes (e.g. AMI
and non-AMI), this score is defined as:
Q31 = 1−
1
N
N∑
i=1
(1− Pi,actual)
2
, (1)
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where N is the number of patients and Pi,actual is the probability assigned
to the ith patient’s actual disease. For example, if patient i is given a 35%
chance of AMI then Pi,AMI = 0.35 and Pi,non-AMI, the probability of non-
AMI is therefore 0.65. If clinical diagnosis indicates AMI, then Pi,actual =
Pi,AMI = 0.35, whereas if the clinical diagnosis is non-AMI, then Pi,actual =
Pi,non-AMI = 0.65.
For any given patient, the best possible classification occurs when Pi,actual =
1, thus the Brier score is based upon the mean square deviation from
this ideal. This mean-square deviation, however, decreases as the classifier
performance improves, contrary to conventional performance measures such
as accuracy. The normalised Brier score, therefore, subtracts this deviation
from unity to give a score of 1 to a perfect classifier (i.e. one which always
gives a probability of 1 to the patient’s actual disease), and a score of 0 to
a totally imperfect classifier. The normalised Brier score can be generalised
to deal with more than two classifications [17].
3.2 Sharpness
The second performance measure, sharpness, is a measure of the confidence
which a classifier has in its outputs, rewarding confident predictions (i.e.
close to unity or zero), rather than indecisive ones. Sharpness is defined as
the expected value of the discriminatory ability:
E [Q31] = 1−
1
N
N∑
i=1
∑
j∈{AMI,
non-AMI}
Pi,j (1− Pi,j)
2
. (2)
Note that as this measure is an expected value, it does not depend
upon the actual disease classification. Here a classifier which assigns a
probability of 1 randomly to diseases would be perfectly sharp, although
the probabilities would be meaningless in practice. This problem leads to
the need for the third performance measure.
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3.3 Reliability
Reliability ties together the ideas of discriminatory ability and sharpness. If
100 patients are each assigned an AMI probability of 0.8, about 80 would be
expected to actually have that disease. If only 50 in fact had the disease, the
classifier is over confident and should have assigned a lower probability to
each patient. On the other hand, if 99 of the patients did have the disease,
then the classifier is diffident, or too cautious. In either case, the classifier
has a poor reliability.
Reliability, therefore, is the difference between how well the classifier
claims it can perform (sharpness) and how well it actually performs (discriminatory
ability). The reliability, Q3, is given by:
Q3 = Q31 − E [Q31] . (3)
Hilden et al.[16] have shown that negative reliability indicates an overconfident
classifier, whilst reliabilities greater than zero reveal a classifier to be diffident.
Reliability on its own is insufficient as a measure of performance: consider
a classifier which simply assigns every patient the same probability of disease,
and that probability is the prevalence of the disease in the population under
investigation. For example, if it is known that 10% of a population have a
certain disease, then assign every patient a probability of 0.1, regardless of
all other evidence. Such a classifier would have perfect reliability, yet would
not provide any additional clinical information.
For this reason, reliability is used and reported in conjunction with
discriminatory ability in this work. (The relationship expressed in equation 3
shows that including sharpness does not provide any additional information.)
3.4 Dot Diagrams
In addition to the numeric measures above, a useful graphical visualisation
technique was presented by Hilden et al. [16] in the form of the dot diagram.
This shows the variation in the AMI and non-AMI probabilities from the
classifier in the form of two rows of points. It therefore provides a rapid
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method for visualising the spread of the probabilistic outputs for a given
disease, see figure 3 for example. Ideally, the points should be bunched to
the right hand side of the diagram (meaning that high probabilities were
assigned to the correct diseases).
3.5 Optimal use of data: Leave-one-out cross-validation
Assessing the performance of a classifier typically involves presenting the
classifier with a number of samples and asking it to classify them. Its
classifications are then compared with a gold standard (clinical diagnosis in
this case) and the performance measures calculated. Ideally the data used
to construct the classifier should be different from that used for assessment
as it will almost certainly perform better on samples already seen.
The problem then arises as to how to divide the finite amount of study
data available between the training set and the test set. One elegant solution
is leave-one-out cross-validation [13]. This entails training a classifier on
N −1 of the available N studies, then testing the classifier on the remaining
one. This process is repeated N times, using a different study for testing
on each occasion, resulting in the construction of N unique, yet similar,
classifiers. Using the results from these N tests, the performance measures
described earlier can then be calculated to provide an unbiased estimate of
the performance of a classifier trained using all N input samples.
4 Classifiers
From the many techniques available for automatic pattern classification,
two were selected for testing in this application. The first, logistic regression
(LR), is one of the simplest techniques used in multivariate pattern recognition
and aims to estimate the class conditional probability distribution. It is well
understood and much less prone to over-fitting when trained on small data
sets than most of the alternatives available. LR classifiers can be viewed
as drawing a series of parallel, n − 1 dimensional, probability contours (i.e.
hyper-planes) through n dimensional space. This is illustrated in figure 1
for the two dimensional case.
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The second method employs a different strategy: rather than trying to
create a boundary in the data space, with points near the boundary assigned
probabilities around 0.5 and those further away given probabilities closer to
0 or 1, Gaussian mixture models (GMMs) estimate the probability density
functions (pdfs) for both the AMI and non-AMI datasets and combine the
results using Bayes’ theorem. These pdfs contain information about the
probability density anywhere in the input space, based on the concentration
of training points in that locality. This means that the GMM can model
arbitrarily complex functions (pdfs), but at the cost of being highly parameterised
and much more likely to overfit the data.
4.1 Data preparation
From the measurements on the 291 unique blood samples used in this work,
some marker concentrations in some samples were found to be too high to be
accurately measured. Eleven CKMB, 30 FABP, 15 myoglobin and 5 cTnI
measurements fell into this category. To facilitate classifier construction,
these out-of-range readings were replaced with values drawn randomly from
a uniform distribution ranging from the maximum value accurately recorded
to 1.1 times this maximum value.
Given the nature of the data and disease, this is not as significant an
issue as it may first appear: the markers are released primarily as a result
of damage to the myocardium (heart muscle); very high levels of markers
therefore are almost certainly indicative of AMI. In fact, only two non-
AMI patients had any marker readings above this threshold: 213 and 267.
Patient 213 had a myoglobin reading out of range, and suffered from a
cardiomyopathy, which would cause damage to the cardiac tissue. Patient
267 suffered from unstable angina, a condition which also causes damage to
the myocardium.
The marker values were then normalised to give each zero-mean and
unit variance, with markers from T0 treated separately to those from T1
during normalisation.
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4.2 Pre-processing and logistic regression
There are numerous techniques for pre-processing data in order to either
remove noise or reduce the dimensionality of datasets (or both). Two procedures
were employed on the normalised marker data: firstly principal component
analysis (PCA), and secondly Fisher discriminant analysis (FDA) [13].
Principal component analysis is commonly used for dimensionality reduction
and involves selecting principal components (PCs) which are linear combinations
of the input variables. The first principal component, PC1, is selected so as
to describe the maximum variation in the data. The second is selected to
contain the maximum variation in the data, subject to the constraint that
it is perpendicular to PC1, and so on. Often the majority of the variation
in the data is captured by the first few PCs.
Fisher discriminant analysis (also known as canonical analysis) can be
viewed as a linear transformation akin to PCA, except that rather than
trying to maximise the variation captured by PC1, it uses class labels to
maximise the separation between classes (AMI and non-AMI in this case).
A detailed description is given in [21].
Logistic regression classifiers were designed and tested using all possible
combinations of the normalised markers, different numbers of PCs and
finally FDA.
4.3 Gaussian mixture models
Bayes’ theorem provides a method for determining the probability, P (AMI|X),
that a patient with a vector of five marker concentrations, X, has AMI, given
only information about the probability density function (pdf) of marker
concentrations in the population of AMI patients P (X|AMI), the pdf of a
similar non-AMI population P (X|non-AMI) and the prevalence of AMI in
the total population under study, P (AMI). Mathematically:
P (AMI|X) =
P (X|AMI)
P (X|AMI) + P (X|non-AMI) · (1− P (AMI)/P (AMI))
. (4)
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The prevalence of the disease can easily be calculated by counting the
number of AMI patients in the sample. Modelling the pdfs of the AMI
and non-AMI populations is somewhat more difficult; in this case Gaussian
mixture models (GMMs) [13] were used.
A GMM of a pdf is created using a combination of Gaussian kernels,
similar to a radial basis function neural network. A GMM was created for
each of the two classifications. One is an estimate of the probability density
function (pdf) for non-AMI patients, the other an estimate of the pdf for
AMI patients. In addition to the number and combination of inputs needed,
the number of centres, or Gaussians, used to construct the model had to
be decided. Once these meta-parameters were selected, the centres and
variances of each Gaussian were determined by the expected maximisation
training algorithm [22].
A sample GMM pdf with three centres is shown in figure 2. When
a new patient is seen with a vector of markers concentrations, X, the
probabilities P (X|AMI) and P (X|non-AMI) can be determined from the
GMMs, and therefore P (AMI|X) follows from equation 4, P (AMI) having
been previously calculated.
5 Results and discussion
Results from a number of different classifiers are described in this section,
together with a discussion of the merits and drawbacks of each, mainly
concerning the sources of bias in the performance estimates. These results
are summarised in tables 1 and 2. All computation was carried out using
Matlab 6 [23] and, where appropriate, the Netlab toolbox [22].
5.1 Logistic regression at admission
Although concentrations of five markers were available at admission (T0),
reducing the dimensionality of a classifier can usually improve its performance
on unseen data, as it is less likely to over-fit the training set. Initially, this
dimensionality reduction was accomplished by omitting markers from the
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data set. For five markers, there are 25 −1 = 31 unique combinations, if the
trivial case of no inputs to the classifier is omitted.
From these 31 possible logistic regression classifiers trained using combinations
of markers taken on admission, the optimum performance (largest Brier
score and NER) occurred with the classifier trained using two of the five
available markers: CKMB and GPBB. In this case, the classifier had a NER
of 0.868 (95% confidence interval: 0.805–0.916), Brier score of 0.904 (with
an associated reliability of -0.013) and AUROCC of 0.913 (standard error:
0.029). The classifiers were ranked according to Brier score to investigate
the relationship between the markers used in construction of each classifier
and its performance. The first notable pattern was that the 16 classifiers
which included CKMB ranked higher than the 15 which did not. Also,
FABP proved least useful, occurring only twice in the top ten, while GPBB,
myoglobin and cTnI appeared 5, 4 and 4 times respectively.
Figure 3 shows the dot diagram for the optimum classifier, where the
good performance obtained in the majority of patients can easily be seen.
Three non-AMI patients, 320, 379 and 239 with P(AMI) below 0.4 were
badly diagnosed. Patient 320 suffered from unstable angina followed by
pulmonary oedema, and proceeded to suffer an MI one week later. Patient
379 was diagnosed with stable angina, cardiac arrthymia and heart failure.
Patient 239 was assigned about a 70% chance of AMI, despite having a
‘non-cardiac’ final diagnosis. The reason for this anomolous classification is
unclear since, although the patient had an MI 3 years previously, this is
unlikely to have affected the results.
A larger number of AMI cases were misclassified, with some 15 out of 50
given less than a 50% chance of AMI. This is primarily due to the first blood
sample having been taken very soon after the AMI, before the markers had
risen to diagnostic concentrations.
5.2 Logistic regression using two samples
This section reports the performance of classifiers constructed using the
concentrations of markers on admission (T0) and at a second time (T1), 1–
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6 hours later. The marker concentrations from T0 and T1 were presented as
separate inputs to the logistic regression classifiers with any combination of
up to 10 inputs. This resulted in 210−1 = 1023 candidate classifiers. From all
these, the best performance (as measured by the Brier score) was produced
when using FABP and myoglobin concentrations at T0 and CKMB, FABP
and cardiac troponin I at T1. This classifier resulted in a NER of 0.955
(CI: 0.904–0.983), Brier score of 0.960, reliability of -0.018 and AUROCC
of 0.959 (SE: 0.023).
The dot diagram for this classifier (figure 4) shows virtually all patients
well classified (i.e. a high probability was assigned by the classifier to the
patient’s actually diagnosis). Only three AMI patients were badly diagnosed
(P (AMI) < 0.4), and similarly, only two non-AMI patients were badly
classified.
The AMI patients in question were 380, 439 and 963. From these, the
first had a T0 reading taken 5h 14min post pain onset, and a T1 sample
taken 6h 29min post pain onset. Both these samples were taken at an early
stage and in very close succession. These two factors may work together
to make it difficult for the classifier to reliably diagnoise AMI. Patient 439
again had markers recorded at a very early stage, T0 at 4h 30mins after
pain onset and T1 at 6h 30. This patient’s markers were also unlikely to
have risen enough in this short space of time to be reliably detected by the
classifier. Finally, patient 963 again had T0 taken very early (4h 09mins
post pain onset) and had a relatively minor (non Q waves, no ST elevation)
infarction.
The non-AMI patients misclassified were patients 267 and 239. Patient
267 had had 4 previous MIs and was diagnosed with unstable angina, a
condition which causes some damage to cardiac tissue. This patient had
elevated levels of all markers, especially myoglobin and cardiac troponin I,
and also showed the rise and fall profile characteristic of AMI patients [24].
Patient 239 has been discussed previously (section 5.1).
Although these results initially appear excellent, they must be tempered
by the knowledge that picking the best classifier from a selection of over
one thousand, based on its performance over test points from leave-one-
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out cross validation, then using the same test set of patients to measure
the performance will lead to bias in the performance measure. Ideally, the
available data should be split, one part being used to train and test the
models and the results used to select the best classifier. This classifier should
then be tested on the remaining part of the data set to provide an unbiased
measure of performance. If this final step is omitted bias is inevitably
introduced in the performance measures. The more models available to
choose from (1023 in this case), the larger the effect of this bias.
5.3 Principal component analysis
The optimum classifiers in each of the previous two sections were produced
from a subset of the five available markers, rather than from the complete
set. This was deliberately done because of the well-documented effect of
overfitting with high-dimensional data (e.g. [13]). Omitting markers is the
simplest way to reduce the dimensionality of the input space but it is
unlikely to provide the best approach since potentially important information
is discarded. Principal component analysis (PCA) often proves a better
technique for reducing the dimensionality of a classifier. It was applied to the
marker concentrations for each patient and the logistic regression analysis
was then repeated, firstly using the T0 sample, then using both the T0 and
T1 samples.
Table 3 and figure 5 show the results of this analysis, where the optimum
performance (highest Brier score and NER plus a reasonable reliability)
resulted from using two PCs. The Brier scores for the best marker combinations
were very similar (table 1), with PCA being just slightly poorer. PCA,
however, may have a slight edge in terms of producing less bias in the
performance measures of the optimum classifier. Here the best classifier
from 5 possibilities is being selected, rather than the best one from 31 when
markers are not pre-processed.
The four non-AMI patients badly classified in figure 5 are from patients 320,
322, 267 and 308. From these, patients 320 and 267 have already been
discussed (section 5.2), patient 308 had elevated marker levels and was
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diagnosed with unstable angina, which results in damage to cardiac tissue.
Patient 322 had elevated marker levels, especially at T0, and was diagnosed
with digoxin toxicity and has a history of angina, which may have caused
minor cardiac damage.
When markers from both T0 and T1 were used (table 4, figure 6), the
results were less clear. Generally speaking, the reliability decreased as more
principal components were included. This is because the number of model
parameters to be determined in training increased with the number of inputs
and the model was then likely to over-fit the data. The poorer figures for
reliability signify that the classifier is more likely to push probabilities to the
extreme values of 0 or 1 regardless of whether that is the correct diagnosis
or not. That is, the classifier’s sharpness increases without a corresponding
increase in its discriminatory ability.
Taking this into account, the optimum classifier can be found by considering
the trade-off between discriminatory ability and reliability, which probably
leaves the best classifier as being the one which uses either 3 or 5 PCs.
The performances of the best classifiers using PCA with inputs from two
consecutive blood samples, however, are poorer than the best classifier found
by crudely omitting markers (table 2). There are two possible contributing
factors: firstly the assumption that directions (principal components) which
capture the maximum variation of the data are the best directions in which
to project the data to provide the optimum separation of two sets of labelled
data may not be valid. Fisher discriminant analysis (section 5.4) attempts
to circumvent this shortcoming but it is not without its own difficulties.
The second factor is the bias in the performance measurement. Selecting
the best classifier, from the set of 10 constructed using PCA preprocessing,
produces a smaller bias than selecting the best from a set of 1023. This is
the most likely cause of the small difference between the results obtained
using, for example the first 4 PCs, and that obtained using the optimum
combination of markers listed above.
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5.4 Fisher discriminant analysis
The second preprocessing method investigated was Fisher discriminant analysis
(FDA), also known as canonical analysis [21]. A summary of the results is
presented in table 7.
Here the performance of both FDA classifiers was slightly worse than
that obtained using either the optimum combination of markers (sections 5.1
and 5.2), or the optimum number of principal components (section 5.3).
There are three possible reasons for the difference in performance measures.
Firstly, the differences are quite small, and certainly well within the confidence
intervals for the performance measures, so that they may be due to random
effects and would disappear if a larger sample was available.
Secondly, they may be caused by bias in the selection of the other
classifiers, as discussed in section 5.3, where an independent test set is
required to assess the performance of the optimum classifier in each case.
As FDA produces only a single variable, no further selection is required,
hence its performance measure is unbiased.
Finally, FDA rests on the assumption that the intra-class characteristics
of each data set (AMI and non-AMI) is comparable [25]. This is not the case
with the current dataset, as non-AMI patients tend to have almost uniformly
low concentrations across all markers, whereas AMI patients have a much
larger variation in their marker concentrations.
5.5 Gaussian mixture models
The final classification approach used was Gaussian mixture models (GMM).
GMM techniques have many more hyper-parameters to be selected than the
previous methods discussed, leaving them much more prone to bias in the
selection of the optimum classifier.
When considering T0 samples, GMMs were constructed with between
1 and 5 centres, using spherical covariance matrices only. Using all 31
combinations of markers, and the 25 combinations of AMI/non-AMI centres
led to 775 unique classifiers. From these, the best classifier (judged according
to Brier score), used only CKMB and GPBB and had four centres in both
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its AMI and non-AMI models. It had a NER of 0.843 (95% CI: 0.777–0.896),
Brier score of 0.898, reliability -0.030 and AUROCC of 0.918 (SE: 0.028).
Its dot diagram is shown in figure 9.
These results have a lower NER and Brier score, and poorer reliability
than the results from either the simple logistic regression, or the logistic
regression with PCA pre-processing. They perform slightly better against
the FDA classifier, having a marginally better Brier score, yet a poorer
reliability and slightly worse NER.
The experiment was repeated using PCA preprocessing and increasing
the number of PCs entered into the classifier whilst varying the number
of centres. The results are listed in table 8, with the dot diagram for the
case of 5 principal components shown in figure 10. Again, these results have
slightly worse diagnostic performance measures and poorer reliability scores
than the logistic regression classifiers.
Given the results are not as good as other, simpler, methods and that the
bias in the results has the potential to also be much larger, it was decided
not to pursue the GMM analysis with two sets of marker measurements.
There is another reason for not investigating GMMs further: the nature
of the Gaussian kernels from which the model is built. Cardiac markers
operate in a moderately predictable manner: as the amount of myocardial
damage increases, the amount of marker released and hence its concentration
in the blood increase. This prior knowledge indicates that if the concentration
of any marker increases, the probability of AMI returned by the classifier
should increase too. The shape and nature of a Gaussian kernel mean
that data points far from its centre are assigned a probability density of
virtually zero. Thus GMMs only cover part of the input space, and are
capable of dividing it up in a smooth, though somewhat arbitrary fashion
if required, rendering them well-suited to multiple classification problems.
Logistic regression, however, divides the entire input space in a manner
consistient with this prior knowledge, see figure 1.
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6 Conclusions
Good performance in estimating the probability of AMI from cardiac marker
concentrations from patients admitted to hospital with chest pain has been
demonstrated. The benefit of measuring the concentrations of several markers
has also been shown, as classifiers with inputs from multiple markers performed
better than those with data from only a single marker.
Including marker concentrations from two sequential times also leads to
a marked improvement in the discriminatory ability of classifiers. This is
probably due to two reasons: firstly, as there is a time lag between an AMI
event and markers entering the bloodstream, the second measurement will
almost certainly have higher marker concentrations than the first, which
may be enough to improve the performance. The second reason is that
knowing how marker concentrations change with time can provide more
information than either marker measurement individually [26, 6].
The new FABPmarker has shown itself as a useful addition for diagnosing
AMI based on two marker readings. From the 1023 possible marker combinations
using samples from both T0 and T1, the top 147 (ordered by Brier Score)
included at least one FABP measurement in their combination. From those
combinations that did not include FABP, the highest Brier Score was 0.932,
compared to 0.955 from the best combination which included FABP. This
large increase in performance provides a basis for suggesting the inclusion
of FABP in regular hospital testing, although the reasons why it failed to
perform as well when using only T0 samples are unclear.
Estimating the probability of AMI, rather than simply opting for a
binary (‘yes’ or ‘no’) classifier, has the potential for higher clinical acceptability
and utility as it aims to assist physician diagnosis rather than compete with
it. Also, estimates of the probability of AMI produced by a classifier can be
adjusted, via Bayes’ theorem, to accommodate variations in the prevalence
of AMI between different populations. This could assist in making the
classifier portable between different locations.
Evaluating the performance of a probabilistic classifier, however, is significantly
more difficult than for binary one, as demonstrated by the identification of
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multiple performance measures, namely discriminatory ability, sharpness
and reliability, in section 3.
This need for multiple performance measures is best observed by the fact
that there is no significant difference between the measures of discriminatory
ability (i.e. non-error rates (or accuracies), Brier scores or AUROCCs) of
the optimum classifier in each section. Alternative criteria must be used to
differentiate between these classifiers. The reliability measure, together with
the complexity of the classifier and appropriate sources of bias must also
be considered. This points to logistic regression with FDA preprocessing as
being a good candidate solution. This lack of difference in certain performance
measures can be viewed as reassuring—all classifiers perform similarly, and
selecting a good candidate does not involve hitting upon a golden preprocessing
algorithm.
Classifiers based on GMMs were over-parameterised which led their poor
reliability scores, reflecting a tendency to overfit the data, meaning that their
probabilities could not be trusted.
Compared to many pattern classification problems (for example, visual
recognition), diagnosing AMI is relatively straightforward—as the concentration
of a marker increases, the probability of AMI should increase too. Simple
classification techniques therefore, such as linear regression, are able to
capture these differences. This is demonstrated in the results presented, and
in unpublished preliminary work, in which more complex artificial neural
networks showed a strong tendency to overfit data and gave poor reliability.
This work has shown good initial progress in estimating the probability
of a patient having suffered an AMI, based upon the concentration of cardiac
markers in their blood. It has been limited by the number of patients
available to it, but classifier performance is expected to improve as more
data becomes available from ongoing clinical trials.
7 Future work
The data used in this study is part of a large ongoing hospital study
which, as of March 2004, has collected 4892 blood samples from some 1500
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eligible patients. Many of these samples are awaiting analysis. As more data
become available, investigations will be extended into three areas: the first
is detecting AMI as early as possible to enable rapid appropriate treatment
of patients. The second is sub-classification of patients along the continuum
coronary syndromes from non cardiac chest pain, through stable angina and
unstable angina to non-Q wave infarctions, where typically a thinner layer of
the heart is damaged, and finally Q wave infarctions which involve the death
of a large area of cardiac tissue. Currently a sharp division is drawn between
unstable angina (designated non-AMI) and non-Q wave MI (designated
AMI). The final area for additional research is for risk stratification or
prognostic information. Eventually it is hoped that a classifier (or classifiers)
may be integrated with the Evidence hardware to produce a device capable
of automatically analysing blood samples and giving relevant information
on a patient’s coronary health care to assist clinicians.
Originality and Contribution
Logistic Regression and Gaussian Mixture Model classifiers have been trained
to estimate the probability of acute myocardial infarction (AMI) based upon
the concentrations of cardiac markers obtained from hospital patient blood
samples. In contrast to previous studies, this work had access to measured
data on five markers simultaneously (CKMB, myoglobin, cTnI, GPBB and
FABP). The last two are more recently discovered and have not been used
in any previous classification system for coronary heart disease.
Logistic Regression, with data pre-processing by Fisher Discriminant
Analysis, provided the best overall classifier based only on blood samples
taken on admission. This gave an accuracy of 0.85 (with a 95% confidence
interval of 0.78-0.91) and a normalized Brier score of 0.89. When a second
sample taken 1 to 6 hours later was included in the classifier, the performance
increased significantly.
The benefit of measuring the concentrations of several markers is shown,
as classifiers with inputs from multiple markers outperformed those for a
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single marker. In particular, the new FABP marker proved to be a useful
addition to the classifier.
8 Acknowledgements
The first author would like to the Department for Employment and Learning,
Northern Ireland, for providing a PhD studentship, and Randox Laboratories
for financial support and provision of data.
References
1. Peterson, S., Rayner, M., Coronary Heart Disease Statistics: 2002
edition, British Heart Foundation, 2002.
2. Wu, A. (Ed.), Cardiac Markers, Pathology and Labratory Medicine,
Humana Press, Totowa, New Jersey, 1998.
3. Goldman, L., Cook, E., Brand, D., Lee, T., Rouan, G., Weisberg, M.,
Acampora, D., Stasiulewicz, C., Walshon, J., Terranova, G., Gottlieb,
L., Kobernick, L., Goldstein-Wayne, B., Copen, D., Daley, K., Brandt,
A., Jones, D., Mellors, J., Jakubowski, R., A computer protocol to
predict myocardial infarction in emergency department patients with
chest pain, The New England Journal of Medicine 318 (13) (1998) 797–
803.
4. Goldman, L., Weinberg, M., Weisberg, M., Olshen, R., Cook, E.,
Sargent, R., Lams, G., Dennis, C., Wilson, C., Deckelbaum, L.,
Fineberg, H., Stiratelli, R., A computer-derived protocol to aid in the
diagnosis of emergency room patients with acute chest pain, The New
England Journal of Medicine 307 (10) (1982) 588–596.
5. Selker, H., Beshansky, J., Griffith, J., Aufderheide, T., Ballin, D.,
Bernard, S., Crespo, S., Feldman, J., Fish, S., Gibler, W., Kiez, D.,
McNutt, R., Moulton, A., Ornato, J., Podrid, P., Pope, J., Salem,
D., Sayre, M., Woolard, R., Use of the Acute Cardiac Ischemia Time-
Insensitive Predictive Instrument (ACI-TIPI) to assist with triage of
patients with chest pain or other symptoms suggestive of acute cardiac
Classification of AMI 25
ischemia: A multicenter, controlled clinical trial, Annals of Internal
Medicine 129 (1) (1998) 845–855.
6. Fesmire, F., Hughes, A., Fody, E., Jackson, A., Fesmire, C., Gilbert,
M., Stout, P., Wojcik, J., Wharton, D., Creel, J., The Eulanger chest
pain evaluation protocol: A one-year experience with serial 12-lead ECG
monitoring, two-hour delta serum marker measurements, and selective
nuclear stress testing to identify and exclude acute coronary syndromes,
Annals of Emergency Medicine 40 (6) (2002) 584–594.
7. Pozen, M., D’Agostino, R., Selker, H., Sytkowski, P., Hood, W., A
predictive instrument to improve coronary-care-unit admission practices
in acute ischemic heart disease, The New England Journal of Medicine
310 (20) (1984) 1273–1278.
8. Tierney, W., Roth, B., Psaty, B., McHenry, R., Fitzgerald, J., Stump,
D., Anderson, K., Ryder, K., McDonald, C., Smith, D., Predictors
or myocardial infarction in emergency room patients, Critical Care
Medicine 13 (7) (1985) 526–531.
9. Harrison, R., Marshall, S., Kennedy, R., Minimum-risk decisions in
the management of suspected heart attack: an application of the
Boltzmann perceptron network, in: Rogers, S. (Ed.), Proceedings of
SPIE. Applications of Artificial Neural Networks III, Vol. 1709, 1992,
pp. 1701–1082.
10. Fraser, H., Pugh, R., Kennedy, R., Ross, P., Harrison, R., A comparison
of back propagation and radial basis functions in the diagnosis of
myocardial infarction, in: Proceedings of the International Conference
on Neural Networks and Expert Systems in Medicine and Health Care,
1994, pp. 76–84.
11. Ellenuis, J., Groth, T., Lindahl, B., Wallentin, L., Early assessment
of patients with suspected acute myocardial infarction by biochemical
monitoring and neural network analysis, Clinical Chemistry 43 (10)
(1997) 1919–1925.
12. Groth, T., Ellenius, J., Provision of decision support for acute
myocardial infarction, United States Patent: 6 443 889 (3 September
2002).
26 Wilson, et al.
13. Bishop, C., Neural Networks for Pattern Recognition, Oxford:
Clarendon Press, 1995.
14. de Dombal, F., Medical Informatics: The Essentials, Butterworth-
Heinemann, Linacre House, Jordan Hill, Oxford OX2 8DP, UK, 1996.
15. Hanley, J., McNeil, B., The meaning and use of the area under a receiver
operator characteristic (ROC) curve, Radiology 143 (1982) 29–36.
16. Hilden, J., Habbema, J., Bjerregaard, B., The measurement of
performance in probabilistic diagnosis: II. Trustworthiness of exact
values of the diagnostic probabilities, Methods of Information in
Medicine 17 (4) (1978) 227–237.
17. Hilden, J., Habbema, J., Bjerregaard, B., The measurement of
performance in probabilistic diagnosis: III. Methods based on
continuous functions of diagnostic probabilities, Methods of Information
in Medicine 17 (4) (1978) 238–246.
18. Habbema, J., Hilden, J., Bjerregaard, B., The measurement of
performance in probabilistic diagnosis: I. The problem, descriptive tools
, and measures based on classification matricies, Methods of Information
in Medicine 17 (4) (1978) 217–226.
19. Habbema, J., Hilden, J., The measurement of performance in
probabilistic diagnosis: IV. Utility considerations in therapeutics and
prognostics, Methods of Information in Medicine 20 (2) (1981) 80–96.
20. Habbema, J., Hilden, J., Bjerregaard, B., The measurement of
performance in probabilistic diagnosis: V. General recommendations,
Methods of Information in Medicine 20 (2) (1981) 97–100.
21. Huang, P., Harris, C., Nixon, M., Comparing different template features
for recognising people by their gait, in: Proceedings of the Ninth British
Machine Vision Conference, Vol. 2, 1998, pp. 639–648.
22. Nabney, I., Netlab: Algorithms for Pattern Recognition, Advances in
Pattern Recognition, Springer, 2002.
23. Inc., T. M., Matlab version 6.1 release 12.1, Software (2001).
24. Armstrong, G., Petry, C., Wagner, G., Wu, A., Reflex algorithm for
early and cost effective diagnosis of myocardial infarctions suitable for
automated diagnostic platforms, European Patent Application number:
Classification of AMI 27
99110216.1 (May 1999).
25. Magee, D., Boyle, R., Improving class seperation in principal component
analysis using delta analysis, research Report: School of Comnputer
Studies, University of Leeds (December 1998).
26. Fesmire, F., Percy, R., Bardoner, J., Wharton, D., Calhoun, F., Serial
creatinine kinase (CK) MB testing during the emergency department
evaluation of chest pain: Utility of a 2-hour delta CK-MB of +1.6ng/ml.,
American Heart Journal 136 (2) (1998) 237–244.
28 Wilson, et al.
List of Figures
1 Example of probability contours for logistic regression classifier. 29
2 Example of probability density function for GMM with three
centres. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3 Dot diagram for logistic regression classifier using CKMB and
GPBB at admission . . . . . . . . . . . . . . . . . . . . . . . 31
4 Dot diagram for logistic regression classifier using FABP,
myoglobin on admission and CKMB, FABP and troponin I
at T1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
5 Dot diagram for logistic regression classifier using first two
principal components at admission . . . . . . . . . . . . . . . 33
6 Dot diagram for logistic regression classifier using first five
principal components at T0 and T1 . . . . . . . . . . . . . . . 34
7 Dot diagram for logistic regression classifier using FDA pre-
processing at T0 . . . . . . . . . . . . . . . . . . . . . . . . . 35
8 Dot diagram for logistic regression classifier using FDA pre-
processing at T0 and T1 . . . . . . . . . . . . . . . . . . . . . 36
9 Dot diagram for GMM classifier using CKMB and GPBB at
admission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
10 Dot diagram for GMM classifier using five principal components
at admission . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
FIGURES 29
0.1–0.2
0.2–0.3
0.3–0.4
0.4–0.5
0.5–0.6
0.6–0.7
> 0.7
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Fig. 1 Example of probability contours for logistic regression classifier.
30 FIGURES
Input 1Input 2
P
ro
b
a
b
il
it
y
D
en
si
ty
-3
-2
-1
0
1
2
3
-3
-2
-1
0
1
2
3
0
0.1
0.2
Fig. 2 Example of probability density function for GMM with three centres.
FIGURES 31
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 3 Dot diagram for logistic regression classifier using CKMB and GPBB at
admission
32 FIGURES
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 4 Dot diagram for logistic regression classifier using FABP, myoglobin on
admission and CKMB, FABP and troponin I at T1
FIGURES 33
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 5 Dot diagram for logistic regression classifier using first two principal
components at admission
34 FIGURES
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 6 Dot diagram for logistic regression classifier using first five principal
components at T0 and T1
FIGURES 35
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 7 Dot diagram for logistic regression classifier using FDA pre-processing at
T0
36 FIGURES
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 8 Dot diagram for logistic regression classifier using FDA pre-processing at
T0 and T1
FIGURES 37
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
N
o
n
-A
M
I
A
M
I
Fig. 9 Dot diagram for GMM classifier using CKMB and GPBB at admission
38 FIGURES
Probability
D
is
ea
se
cl
a
ss
ifi
ca
ti
o
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
1
2
Fig. 10 Dot diagram for GMM classifier using five principal components at
admission
FIGURES 39
List of Tables
1 Comparison of classification techniques based upon blood
samples taken at admission (T0) . . . . . . . . . . . . . . . . 40
2 Comparison of classification techniques based upon blood
samples taken at T0 and T1 . . . . . . . . . . . . . . . . . . . 41
3 Performance of logistic regression classifier with increasing
numbers of principal components as inputs using samples on
admission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4 Performance of logistic regression classifier with increasing
numbers of principal components as inputs and two time
samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
5 Variation captured by each principal component using samples
on admission. . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
6 Variation captured by each principal component using samples
at T0 and T1. . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
7 Performance of classifiers trained using FDA preprocessing.
The ‘number of samples’ column refers to the number of
blood samples used from a given patient, so that ‘1’ indicated
only blood taken on admission was used, and ‘2’ indicates
blood taken on admission and at a later time. . . . . . . . . . 46
8 Performance of GMM classifier with PCA pre-processing . . . 47
40 TABLES
Classifier NER AUROCC Brier score Reliability
Logistic Regression (LR) 0.868 0.913 0.904 -0.013
LR with PCA 0.862 0.906 0.895 -0.018
LR with FDA 0.849 0.908 0.887 -0.001
GMM 0.843 0.918 0.896 -0.030
GMM with PCA 0.855 0.840 0.861 -0.099
Table 1 Comparison of classification techniques based upon blood samples taken
at admission (T0)
TABLES 41
Classifier NER AUROCC Brier score Reliability
Logistic Regression (LR) 0.955 0.959 0.960 -0.018
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